Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 2/20 | 0.39 |
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.35 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 9/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | TSPO | P30536 | 1/20 | 0.33 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.33 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.33 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.33 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | GHSR | Q92847 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16939238 | 0.90 | MME (0.36) | CHRM3 | |
| SCHEMBL14900454 | 0.83 | GRM2 (0.45) | RORCP2RX7MCHR1MAOB | |
| SCHEMBL14900465 | 0.81 | RORC (0.40) | RORCMMEL1P2RX7MCHR1LMNA | |
| SCHEMBL18597967 | 0.79 | RORC (0.39) | RORCCXCR3P2RX7ROCK2PTGER1 | |
| SCHEMBL14900495 | 0.78 | HCRTR1 (0.41) | — | |
| SCHEMBL14902419 | 0.78 | MME (0.38) | RORCMMEL1P2RX7LMNAPTGER1 | |
| SCHEMBL14900434 | 0.76 | POLB (0.36) | LMNA | |
| SCHEMBL16939243 | 0.74 | GRM2 (0.44) | CHRM3 | |
| SCHEMBL16939237 | 0.72 | CHRM3 (0.36) | P2RX7MCHR1PTGER1PTGER4PTGER3 | |
| SCHEMBL16930525 | 0.70 | USP30 (0.36) | CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12016835-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2024-06-25 | — | — | US | disclosed |
| US-20230285340-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-09-14 | — | — | US | disclosed |
| US-20180194718-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-07-12 | — | — | US | disclosed |
| US-20170368010-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-12-28 | — | — | US | disclosed |
| US-9840460-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-12-12 | — | — | US | disclosed |
| US-20170327459-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-11-16 | — | — | US | disclosed |
| US-9688616-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-06-27 | — | — | US | disclosed |
| US-9682052-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-06-20 | — | — | US | disclosed |
| US-20170015619-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-01-19 | — | — | US | disclosed |
| US-9428457-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-08-30 | — | — | US | disclosed |
| US-20160074352-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-03-17 | — | — | US | disclosed |
| US-20150376128-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-12-31 | — | — | US | disclosed |
| US-9150500-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-10-06 | — | — | US | disclosed |
| US-9096496-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-08-04 | — | — | US | disclosed |
| US-20150166469-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-06-18 | — | — | US | disclosed |
| US-8901169-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-12-02 | — | — | US | disclosed |
| US-20140343138-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-11-20 | — | — | US | disclosed |
| US-20140256702-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20130109639-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC | 2013-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285340-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | RORC 4543/4885MMEL1 213/4885CXCR3 4059/4885 |
| US-20140256702-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | RORC 4528/4885MMEL1 172/4885CXCR3 2806/4885 |
| US-20130109639-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | RORC 4543/4885MMEL1 213/4885CXCR3 4059/4885 |
| US-20170368010-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | RORC 4543/4885MMEL1 213/4885CXCR3 4059/4885 |
| US-20170015619-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | RORC 4528/4885MMEL1 172/4885CXCR3 2806/4885 |
| US-20150376128-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | RORC 4528/4885MMEL1 172/4885CXCR3 2806/4885 |
| US-20150166469-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | RORC 4528/4885MMEL1 172/4885CXCR3 2806/4885 |
| US-20180194718-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | RORC 4528/4885MMEL1 172/4885CXCR3 2806/4885 |
| US-20160074352-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | RORC 4543/4885MMEL1 213/4885CXCR3 4059/4885 |
| US-20140343138-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | RORC 4543/4885MMEL1 213/4885CXCR3 4059/4885 |
| US-20170327459-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | RORC 4528/4885MMEL1 172/4885CXCR3 2806/4885 |
| US-12016835-B2 | Neprilysin inhibitors | MME, REN, ACE | RORC 4543/4885MMEL1 213/4885CXCR3 4059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.